Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025
04:00pm, Monday, 31'st Mar 2025
BOSTON , March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursda
KalVista Pharmaceuticals Announces Early Completion of Enrollment in KONFIDENT-KID Pediatric HAE Trial
07:00am, Tuesday, 25'th Mar 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the completion of enrollment in the open-label KONFIDENT-KID clinical trial of seb
Is it Apt to Retain HAE Stock in Your Portfolio for Now?
11:40am, Tuesday, 18'th Mar 2025
Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics.
Haemonetics Announces Executive Leadership Updates
04:10pm, Monday, 03'rd Mar 2025
Frank Chan joins Haemonetics as Executive Vice President, Chief Operating Officer; Roy Galvin named Executive Vice President, Chief Commercial Officer BOSTON , March 3, 2025 /PRNewswire/ -- Haemonet
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet ne
Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference
06:00am, Monday, 24'th Feb 2025
BOSTON , Feb. 24, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th A
TAKHZYRO Solution for Injection in 2 mL Pre-Filled Pen is Now Approved to Facilitate Subcutaneous Administration in Adolescent (Aged 12 Years and Above) and Adult Patients with HAE.1 The Pre-Filled Pe
ANDEMBRY® is a first-in-class monoclonal antibody treatment that inhibits activated Factor XII (FXIIa), the initiating factor in the HAE pathway, and offers the first pre-filled pen presentation enab
Astria Therapeutics: A High-Conviction Bet On HAE
10:32pm, Monday, 17'th Feb 2025
Astria Therapeutics' strong cash position and efficient spending provide a financial runway through mid-2027, reducing dilution risk and supporting pivotal trials for navenibart and STAR-0310. Navenib
European Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
07:00am, Thursday, 13'th Feb 2025
- ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits plasma protein factor XIIa, which initiates the cascade of events leading t
HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket
10:16am, Friday, 07'th Feb 2025
Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion.
Haemonetics Corporation (HAE) Q3 2025 Earnings Call Transcript
12:19pm, Thursday, 06'th Feb 2025
Haemonetics Corporation (NYSE:HAE ) Q3 2025 Earnings Conference Call February 6, 2025 8:30 AM ET Company Participants Olga Guyette - Vice President, Investor Relations and Treasury Christopher Simon -
Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:36am, Thursday, 06'th Feb 2025
Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall S
Haemonetics (HAE) Q3 Earnings Meet Estimates
08:41am, Thursday, 06'th Feb 2025
Haemonetics (HAE) came out with quarterly earnings of $1.19 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $1.04 per share a year ago.
Haemonetics 3rd Quarter Fiscal Year 2025 Earnings Release Available on Investor Relations Website
06:00am, Thursday, 06'th Feb 2025
Financial release accessible online BOSTON , Feb. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its third quarter fiscal year 2025, which ended Dece
